Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases
- 1 May 2020
- journal article
- review article
- Published by Future Medicine Ltd in Future Oncology
- Vol. 16 (14), 899-909
- https://doi.org/10.2217/fon-2020-0094
Abstract
Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).This publication has 69 references indexed in Scilit:
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab eraThe Breast, 2013
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtypeBreast Cancer Research and Treatment, 2012
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast CancerPharmaceutical Research, 2011
- microRNA-34c is a novel target to treat dementiasThe EMBO Journal, 2011
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesJournal of Neuro-Oncology, 2011
- Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (UCH-L1) in Severe Traumatic Brain Injury Patient BiofluidsJournal of Neurotrauma, 2011
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonizationClinical & Experimental Metastasis, 2008
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003